– UK, London – Small Pharma Inc. (TSX: DMT | OTC: DMTTF), a neuro-pharmaceutical company focused on psychedelic-assisted therapies, today announced the appointment of Paul Maier to its Board as an Independent Non-Executive Director.
“We are delighted to welcome someone of Paul’s calibre to the Board of Small Pharma. His appointment adds important expertise and capabilities to the Board as he brings broad financial and leadership experience as well as a relevant network in the North American capital markets which will be invaluable as we look to grow the business. With our first product in clinical trials and a promising pipeline of candidates, a strong diversified Board is essential in guiding the business through this critical growth period.” commented Board Chair, Lyne Fortin.
Mr. Maier has also been appointed as a member of the Audit Committee and Corporate Governance and Nominating Committee and Chair of the Compensation Committee.
About Paul Maier
Paul Maier joins Small Pharma with over 30 years’ experience in senior executive roles across the biopharmaceutical and biotech industry. He has a successful track record at U.S. publicly listed biotech companies, raising over US$1.5bn in equity and debt financing across his career, as well as extensive expertise in company and product acquisitions and IPOs. Mr. Maier has served as CFO at Sequenom, Inc. and Ligand Pharmaceuticals, Inc. He currently serves on the board of 4D pharma plc (NASDAQ: LBPS), Eton Pharmaceuticals, Inc. (NASDAQ: ETON), Biological Dynamics, and International Stem Cell Corporation (OTCBB: ISCO). He previously served on the board of other publicly listed companies, including Ritter Pharmaceuticals, Inc., Apricus Biosciences, Inc., and MabVax Therapeutics Holdings, Inc. Mr. Maier holds an MBA from the Harvard Graduate School of Business.
Mr. Maier said: “It is an honor to join the Small Pharma Board at this exciting juncture for the Company. I look forward to working with the dedicated Board and talented management team to build upon the work that has been done to date and continue to create long term value from this innovative therapy for all stakeholders involved in mental health.”
About Small Pharma
Small Pharma is a neuropharmaceutical company specialized in IP led development of novel treatments for mental health conditions, with a focus on depression. Small Pharma initiated a clinical program into N, N-dimethyltryptamine-assisted therapy in February 2021. This program includes a Phase I/IIa trial on its lead candidate alongside development of a robust pipeline of proprietary preclinical assets.
For more information : https://smallpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
